Hans Schreiber to Antigens, Neoplasm
This is a "connection" page, showing publications Hans Schreiber has written about Antigens, Neoplasm.
Connection Strength
4.297
-
Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun. 2011 Jun 30; 11:2.
Score: 0.300
-
Specificity in cancer immunotherapy. Semin Immunol. 2008 Oct; 20(5):276-85.
Score: 0.245
-
Cancer. Quo vadis, specificity? Science. 2008 Jan 11; 319(5860):164-5.
Score: 0.236
-
A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science. 2006 Oct 13; 314(5797):304-8.
Score: 0.216
-
Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 2005 Jun 06; 5:8.
Score: 0.197
-
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.
Score: 0.182
-
Bystander elimination of antigen loss variants in established tumors. Nat Med. 2004 Mar; 10(3):294-8.
Score: 0.180
-
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity. 2002 Dec; 17(6):737-47.
Score: 0.165
-
Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
Score: 0.153
-
Point mutation in essential genes with loss or mutation of the second allele: relevance to the retention of tumor-specific antigens. J Exp Med. 2001 Aug 06; 194(3):285-300.
Score: 0.151
-
Multiple cancer-specific antigens are targeted by a chimeric antigen receptor on a single cancer cell. JCI Insight. 2019 11 01; 4(21).
Score: 0.133
-
Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide. J Immunother. 1998 Jul; 21(4):277-82.
Score: 0.122
-
Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication. Cancer Immunol Res. 2017 02; 5(2):127-136.
Score: 0.110
-
Unique tumor antigens redefined as mutant tumor-specific antigens. Semin Immunol. 1996 Oct; 8(5):289-93.
Score: 0.108
-
Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens. 1996 May; 47(5):399-407.
Score: 0.105
-
Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. Clin Cancer Res. 2016 06 01; 22(11):2734-43.
Score: 0.102
-
Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res. 1995 Nov 01; 55(21):5094-100.
Score: 0.101
-
Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol. 2015 Apr; 33:112-9.
Score: 0.097
-
A unique tumor antigen produced by a single amino acid substitution. Immunity. 1995 Jan; 2(1):45-59.
Score: 0.096
-
Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur J Immunol. 1993 Nov; 23(11):2770-6.
Score: 0.088
-
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med. 1993 Sep 01; 178(3):933-40.
Score: 0.087
-
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2013 Aug; 1(2):123-33.
Score: 0.087
-
DNA sequence analysis of T-cell receptor genes reveals an oligoclonal T-cell response to a tumor with multiple target antigens. Cancer Res. 1993 Feb 15; 53(4):840-5.
Score: 0.084
-
MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR. Cancer Immunol Immunother. 2013 Feb; 62(2):359-69.
Score: 0.081
-
Tumor antigens. Annu Rev Immunol. 1992; 10:617-44.
Score: 0.078
-
Cancer. Awakening immunity. Science. 2010 Nov 05; 330(6005):761-2.
Score: 0.072
-
Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. J Immunol. 2009 Aug 01; 183(3):1828-37.
Score: 0.065
-
Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med. 1989 Jul 01; 170(1):217-32.
Score: 0.065
-
Tumor-specific antigens and tumor-specific mutant proteins in mouse and man. Haematol Blood Transfus. 1989; 32:284-8.
Score: 0.063
-
Tumor-specific immune responses. Semin Immunol. 2008 Oct; 20(5):265-6.
Score: 0.062
-
Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res. 2008 Mar 01; 68(5):1563-71.
Score: 0.059
-
Unique tumor-specific antigens. Annu Rev Immunol. 1988; 6:465-83.
Score: 0.059
-
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med. 2007 Jan 22; 204(1):49-55.
Score: 0.055
-
Identification of a gene encoding a tumor-specific antigen that causes tumor rejection. Haematol Blood Transfus. 1987; 31:308-13.
Score: 0.055
-
Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases. Oncoimmunology. 2025 Dec; 14(1):2514041.
Score: 0.049
-
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire. J Immunother Cancer. 2025 May 02; 13(5).
Score: 0.049
-
Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J Exp Med. 2003 Apr 21; 197(8):985-95.
Score: 0.042
-
CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes. Transplantation. 1993 Jun; 55(6):1349-55.
Score: 0.021
-
IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8158-63.
Score: 0.021
-
MHC class I restricted T cells and immune surveillance against transplanted ultraviolet light-induced tumors. Semin Cancer Biol. 1991 Oct; 2(5):321-8.
Score: 0.019
-
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007 Aug 01; 179(3):1960-8.
Score: 0.014
-
Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med. 2005 Mar 07; 201(5):779-91.
Score: 0.012
-
[CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon]. Dtsch Med Wochenschr. 1984 Dec 21; 109(51-52):1949-54.
Score: 0.012